Apellis Pharmaceuticals Stock News

The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH)

WALTHAM, Mass. and STOCKHOLM, Sweden, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today new d

WALTHAM, Mass. and STOCKHOLM, Sweden, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today new data demonstrating that Empaveli™/Aspaveli ® (pegcetacoplan) provides consistent, sustained normalization of clinical measures across patients with paroxysmal nocturnal hemoglobinuria (PNH) who are treatment-naïve and patients with baseline hemoglobin levels greater than or equal to 10.0 g/dL. The data were presented at the American Society of Hematology Annual Meeting (ASH) taking place December 11 - 14, 2021.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) price on Friday, December 10, rose 0.87% above its previous days close as an upside momentum from buyers pushed the stocks value to $41.88. A look at the stocks price movement, the close in the last trading session was $41.52, moving within a range at $41.59 and $42.65. The beta value A Stock Analysis Of Apellis Pharmaceuticals Inc.s (APLS) Read More »

Wall Street analysts expect that Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) will post ($1.27) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Apellis Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($1.65). Apellis Pharmaceuticals reported earnings of []

Roth Capital reiterated their neutral rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report sent to investors on Monday, PriceTargets.com reports. Roth Capital currently has a $40.00 price objective on the stock, down from their previous price objective of $46.00. Other research analysts have also recently issued research reports about the stock. Jefferies []

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) has a beta value of 1.65 and has seen 1.11 million shares traded in the last trading session. The company, currently valued at $3.62B, closed the last trade at $42.08 per share which meant it lost -$0.78 on the day or -1.82% during that session. The APLS stock price is -73.48% Apellis Pharmaceuticals Inc. (APLS) Is Another Fantastic Bargain Stock Read More »

Roth Capital reissued their neutral rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report sent to investors on Monday morning, Analyst Ratings Network reports. The firm currently has a $40.00 target price on the stock, down from their prior target price of $46.00. A number of other equities analysts have also recently issued [] The post Apellis Pharmaceuticals (APLS) Neutral Rating Reaffirmed at Roth Capital appeared first on ETF Daily News .

Wall Street brokerages forecast that Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) will post sales of $18.33 million for the current quarter, Zacks reports. Six analysts have provided estimates for Apellis Pharmaceuticals earnings, with the lowest sales estimate coming in at $5.64 million and the highest estimate coming in at $70.03 million. Apellis Pharmaceuticals reported sales of $250.00 []

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pr

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET. The conference will be held in a virtual meeting format.

Bicycle Therapeutics (NASDAQ:BCYC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends. Analyst Ratings This is a summary of recent ratings and price targets for Bicycle Therapeutics and []

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pre

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has received an average rating of Buy from the fourteen research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average []